Related Experiment Video

Updated: May 24, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

375

Reply to: "STRIDE's efficacy and safety in Asian hepatocellular carcinoma"

George Lau1, Ghassan K Abou-Alfa2, Stephen L Chan3

  • 1Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong Special Administrative Region of China.

Journal of Hepatology
|March 2, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.4K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.0K

Related Experiment Videos

Last Updated: May 24, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

375
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.4K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

Articles linked to this work by shared authors, journal, and citation graph.

Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90Y Radioembolization with Immunotherapy in HCC.

Radiology·2026

Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

The Lancet. Oncology·2026

Clinical and LAT1 Biomarker Correlates of Clinical Benefit from Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer: A Post Hoc Analysis.

Cancers·2026

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma.

JCO precision oncology·2026

APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.

Hepatology international·2026

Barriers to Viral Hepatitis Elimination and New Strategies to Overcome Them in Low- and Middle-Income Countries.

Journal of hepatology·2026

Emerging strategies for hepatocellular carcinoma surveillance: abbreviated MRI, biomarkers and benefit stratification.

Journal of hepatology·2026

Artificial intelligence and personalised medicine in liver cancer.

Journal of hepatology·2026

Spleen stiffness measurement rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis.

Journal of hepatology·2026

Serum HBsAg cannot distinguish cccDNA activity from integrated HBV DNA expression in chronic hepatitis B virus infection.

Journal of hepatology·2026

Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.

Journal of hepatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us